Skip to content
OpenCapital
Get started

Zevra Therapeutics, Inc. ZVRA Q3 2025 earnings

Reported November 5, 2025 · After market close

Revenue$26.1MMiss by $578.9K
EPS-$0.01Beat by $0.01
Revenue estimate$26.6M
EPS estimate-$0.02

Next report

Aug 5, 2026 (In 1 week)
Revenue estimate$33.9M
EPS estimate$0.08

Financials

Q3 2025

Income statement

See full
Revenue$26.1M+605%
Gross profit$24.8M+1,683%
Operating income$4.1M+115%
Net income-$544.0K+98.4%
EPS (diluted)-$0.01+98.6%

Balance sheet

See full
Cash & equivalents$54.4M+0.7%
Total debt$62.7M+4.7%
Total equity$133.2M+90.9%
Total assets$270.1M+41.0%

Cash flow

See full
CapEx$554.0K—

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$533.84M+83.6%
Enterprise value$542.12M+82.7%
P/E15.1×—
P/S6.3×-5.5×

Profitability

See full
Gross margin80.7%+13.5pp
Operating margin-103.9%-43.0pp
Net margin41.9%+22.1pp

Returns & leverage

See full
Return on equity34.8%+19.4pp
Debt / equity0.5×-0.4×
Current ratio8.6×+5.7×

Segments

By product

See full
MIPLYFFA$22.4M+787%
OLPRUVA$100.0K—

By segment

See full
Reportable Segment$26.1M+605%

Versus estimates

Revenue

Q1 2026$36.2MBeat by $4.3MQ4 2025$34.1MBeat by $6.0M
Q3 2025$26.1MMiss by $578.9K
Q2 2025$25.9MBeat by $1.4MQ1 2025$20.4MMiss by $672.6KQ4 2024$12.0MMiss by $4.6M

Diluted EPS

Q1 2026$0.18Beat by $0.12Q4 2025$1.16Beat by $1.11
Q3 2025-$0.01Beat by $0.01
Q2 2025$1.21Miss by $0.98Q1 2025-$0.06Beat by $0.15Q4 2024-$0.67Miss by $0.28

Ask the moment Zevra Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Zevra Therapeutics, Inc. report Q3 2025 earnings?
Zevra Therapeutics, Inc. (ZVRA) reported Q3 2025 earnings on November 5, 2025 after market close.
What were Zevra Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Zevra Therapeutics, Inc. reported revenue of $26.1M and eps of $-0.01 for Q3 2025.
Did Zevra Therapeutics, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $26.6M by $578.9K. EPS beat the consensus estimate of $-0.02 by $0.01.
How did Zevra Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 605.4% from $3.7M a year earlier and eps grew 98.6% from $-0.69.
Where can I find Zevra Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001434647-25-000009) and the 10-Q periodic report (0001434647-25-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.